Artivion, Inc. (AORT)

Environment story

Artivion exhibits material environmental gaps. Scope 1, 2, and 3 emissions are undisclosed, triggering automatic -15 penalty. No net-zero target year is disclosed (-15). The company relies on EtO sterilization (ethylene oxide) for certain On-X products and components, exposing it to regulatory and litigation risk; increased activism and facility closures documented. PFAS use in medical devices and packaging noted but impact unquantified. The company acknowledges environmental regulation risk but provides no decarbonization infrastructure investments. MDR transition compliance and supply-chain sustainability management are mentioned but not linked to emissions reductions. Greenwashing detection: no carbon offsets detected, but absence of supply-chain emissions disclosure prevents full audit. Environmental score reflects high uncertainty and regulatory exposure.

Social story

Artivion social performance is moderately weak. CEO-to-worker pay ratio is undisclosed but likely elevated (no deduction applied pending confirmation). Turnover and union standing are undisclosed; no documented union-suppression activities or major strikes within 24 months reported. Leadership diversity metrics are not disclosed; absence of data prevents scoring penalty but signals governance opacity. Supply-chain ethics: the company acknowledges dependence on OPOs (organ procurement organizations) and tissue banks but provides no human-rights audit or conflict-minerals policy. Workforce is described as 'specialized' and subject to competitive talent pressure; no diversity, pay-equity, or civil-rights audit disclosures found. The company references compliance with AdvaMed, MedTech Europe, and APACMed codes of conduct but no EEO-1 disclosure or HRC CEI score provided. Overall, social audit reveals low transparency and limited proactive DEI or supply-chain ethics programs.

Governance story

Artivion governance exhibits moderate weaknesses. Share structure is single-class (Delaware incorporation as of January 1, 2022); no dual-class voting penalty applied. Board independence percentage is undisclosed; absence of data prevents penalty calculation. Lobbying expenditures are undisclosed but risk-factor discussion indicates active engagement on EtO regulation, PFAS, MDR, and healthcare policy—some potentially designed to maintain operational flexibility rather than weaken environmental regulation explicitly. The company faces active litigation and regulatory proceedings: cybersecurity incident in Q4 2024 with ongoing insurance claims and remediation costs; Italian government medical device overpayment disputes; FDA reclassification risk for CryoValve SGPV (potential Class III); PROACT Xa trial halt and On-X mitral labeling delays; European MDR transition disruptions; and shareholder activism risk flagged. No antitrust proceedings explicitly stated, but product-liability exposure and off-label promotion risk are noted. SEC consent decrees are not mentioned. Governance opacity regarding lobbying direction and board independence limits full scoring but does not reveal explicit deregulation efforts. Anti-takeover provisions (Delaware business-combination moratorium, blank-check preferred stock, director appointment authority) present in certificate and bylaws.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Artivion, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Artivion, Inc. in the app for interactive charts and portfolio building.

More in Healthcare